ENPP1 is reviewed as an extracellular nucleotide-hydrolyzing enzyme. The most clearly established reactions are ATP-to-AMP/PPi hydrolysis and cGAMP destruction. ATP-derived PPi regulates mineral deposition; the immune effects of cGAMP hydrolysis are a separate substrate consequence. Human cell experiments, mouse genetics, purified mouse extracellular protein and engineered commercial reagents provide complementary evidence with distinct limits. Exact original URLs, sections, figures and access limits are recorded in the source guide.
All 97 imported annotation contexts have individual decisions. Imported terms, evidence codes, citations, supporting entities and flags remain unchanged. Supported generic protein interactions are retained as non-core; no new annotation or publication quotation is added.
The broad membrane, hydrolase and metal-binding rows are refined to existing supported specific locations, reactions and metals. Cell counts with unchanged viability support population-proliferation regulation, rather than individual-cell-size growth. Bone rescue supports mineralization regulation rather than direct mineral deposition. Phosphomonoesterase and nucleotide-diphosphatase chemistry are distinguished. The intracellular and systemic phosphate-homeostasis source claims are assessed against the papers' actual PPi versus Pi measurements; these findings do not exclude ENPP1 effects on phosphate physiology in other settings.
PPi generation is distinguished from directed PPi movement. Read mouse donor originals measure uptake of administered PPi, genetic effects on its abundance, or rescue by supplementation, without establishing ENPP1 as the transport agent. This is a process-scope judgment, not an inference from donor count or a claim that PAINT placed the ancestral node incorrectly. The unread human transport paper remains explicitly unresolved.
Uncertainty remains for exact oligonucleotide cleavage, dinucleotide-pyrophosphate cleavage, cyclic-AMP hydrolysis, PAPS claims, selected source-specific substrate assays, lysosomal enrichment, melanocyte differentiation and the developmental scope of a rule-derived organ annotation. The cGAMP reaction does not independently establish dinucleotide phosphatase under its P–O–P-bond ancestry. ENPP1 regulation can contribute to a developmental process; lack of a role as developmental machinery is not a reason to reject the broad organ-development annotation. The unresolved distinction is between organ formation/progression and mineral balance in an existing organ.
The human record contains a 925-amino-acid type-II membrane protein and a 103–925 secreted processed chain inferred by similarity to mouse. The record does not supply an alternative splice-isoform series. No P22413-1 identifier or alternate splice product is invented. Soluble human plasma PC-1 is independently observed, but the human cleavage site and each product's oligomeric state are not established by that observation alone. A processed chain is not placed in the schema's splice-specific alternative_products field.
The current commercial datasheet associated with the cGAMP study describes an ENPP1/ENPP2 hybrid and postdates the historical experiment. Its preparation-specific numerical kinetics cannot be assigned automatically to full-length natural human ENPP1. Native human knockdown and mouse knockout observations remain independent support. Mouse structural residue numbers are not copied onto the human sequence. Full-length expression constructs, truncated extracellular constructs and engineered fusions are kept distinct from naturally processed products.
The initial acquisition produced exactly 97 raw QuickGO records, 97 TSV rows and 97 seeded YAML contexts. The original 51-PMID acquisition plan was preserved. PMID:23027977 was recorded as an explicit post-intake addition; two further mouse donor originals, PMID:28701330 and PMID:28704395, were added for the bounded PPi-transport source check. The acquisition record retains 54 normal publication caches: nine copied existing-main caches and 45 newly fetched caches. Their bytes and availability metadata were not edited. Only caches cited by the review or its public notes/source guide are included in the publication payload; the wider genuine-fetch inventory remains preserved in private receipts.
The genuine Falcon deep-research request and its Perplexity-lite fallback failed with provider access/quota errors. No provider report was fabricated. Original papers, official database records and manual notes supply the scientific review; the provider failure is preserved in acquisition receipts. No custom sequence alignment, phylogenetic reconstruction, docking, kinetic refit or coordinate reanalysis is claimed.
The completed annotation assessment contains 39 ACCEPT, 21 KEEP_AS_NON_CORE, 21 UNDECIDED, 6 MARK_AS_OVER_ANNOTATED and 10 MODIFY decisions. Two core units describe ATP-to-AMP/PPi and cGAMP-to-AMP/GMP hydrolysis. The ATP unit includes unsigned regulation of bone mineralization; the cGAMP unit adds no new immune-process assertion. These are distinct substrate reactions, not new products or separate catalytic domains. Plasma-membrane and soluble extracellular locations are independently supported; this does not claim that every natural product was separately assayed against every substrate. Product boundaries remain in the source guide rather than an invented functional splice class.
The genuine just validate human ENPP1 check passed schema, term, reference and best-practice validation with no errors and seven advisories. Two concern supported generic protein binding retained as non-core under the curation policy; three concern missing structured propagation metadata for the explicitly discussed IBA uncertainties/transport assessment; two flag deliberate source-specific differences for PPi transport and UTP activity. Their scientific reasons remain in the individual reviews and source guide. The repository status checker confirms DRAFT because advisories remain, although every imported annotation has been assessed. Separate preservation checks confirmed unchanged imported source fields and all 54 acquired normal caches, reference-title consistency and no new quotations; these checks do not replace scientific review.
ENPP1 supplies ATP-to-AMP/PPi chemistry and also hydrolyzes cGAMP; the original-source guide distinguishes the enzyme preparations and the roles of CD73, TNAP and receptors. The INSR study identifies the partner in receptor-capture/co-immunoprecipitation assays (Methods and Figs. 2–3), supporting a specific binding refinement. The patient-fibroblast study separates ENPP1 transcript measurement (Fig. 2D), CD73 transcript/activity (Fig. 2E–F), and a proposed downstream TNAP-expression model (Discussion/Fig. 7). These inspected readouts raise a process-specificity concern, but the unread detailed supplementary methods preclude rejecting the experimental annotation. Its support remains UNDECIDED pending clarification, without ruling out downstream expression regulation. The broad SMB mapping is judged separately for polysaccharide recognition and scavenger-ligand internalization.
The 2017 substrate study combines biochemistry and modeling. Its externally recovered indexed abstract/previews and its bibliography-only normal cache are distinct evidence objects. Complete Methods and Table 1 remain unavailable. The follow-up makes three action changes: insulin-receptor binding refinement, unresolved experimental gene-expression support and polysaccharide mapping over-annotation. The resulting counts are 39 ACCEPT, 20 KEEP_AS_NON_CORE, 21 UNDECIDED, 6 MARK_AS_OVER_ANNOTATED and 11 MODIFY. Imported annotations, products and all normal caches are unchanged; no new annotation or publication quotation is added.